A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies
- PMID: 31843752
- DOI: 10.1158/1078-0432.CCR-19-3670
A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies
Abstract
CDK9-specific inhibition with AZD4573 impairs cancer-promoting gene expression such as MCL-1 and has been proven effective in hematologic malignancies preclinical models. This new clinical candidate should be further explored in the clinic not only as a monotherapy but also in combination with BH3 mimetics to prevent treatment resistance.See related article by Cidado et al., p. 922.
©2019 American Association for Cancer Research.
Comment in
-
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.Clin Cancer Res. 2020 Feb 15;26(4):922-934. doi: 10.1158/1078-0432.CCR-19-1853. Epub 2019 Nov 7. Clin Cancer Res. 2020. PMID: 31699827
Comment on
-
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.Clin Cancer Res. 2020 Feb 15;26(4):922-934. doi: 10.1158/1078-0432.CCR-19-1853. Epub 2019 Nov 7. Clin Cancer Res. 2020. PMID: 31699827
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
